Compare MHH & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | ADAG |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.7M | 146.3M |
| IPO Year | 2008 | 2020 |
| Metric | MHH | ADAG |
|---|---|---|
| Price | $6.26 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 15.5K | ★ 184.4K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $198,943,000.00 | N/A |
| Revenue This Year | $2.93 | $3,688.61 |
| Revenue Next Year | $8.93 | $17.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.51 | $1.33 |
| 52 Week High | $10.91 | $4.58 |
| Indicator | MHH | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 68.83 |
| Support Level | $5.51 | $1.64 |
| Resistance Level | $7.75 | N/A |
| Average True Range (ATR) | 0.37 | 0.36 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 65.09 | 51.13 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.